{"version":"1.0","provider_name":"Eczema Society of Canada","provider_url":"https:\/\/eczemahelp.ca\/fr\/","author_name":"support@1dea.ca","author_url":"https:\/\/eczemahelp.ca\/fr\/author\/support1dea-ca\/","title":"Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib) | Eczema Society of Canada","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"VU9AkwGiDi\"><a href=\"https:\/\/eczemahelp.ca\/fr\/un-medecin-vous-parle-dopzelura-ruxolitinib\/\">Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/eczemahelp.ca\/fr\/un-medecin-vous-parle-dopzelura-ruxolitinib\/embed\/#?secret=VU9AkwGiDi\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Un m\u00e9decin vous parle d\u2019Opzelura\u00ae (ruxolitinib)\u00a0\u00bb &#8212; Eczema Society of Canada\" data-secret=\"VU9AkwGiDi\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/eczemahelp.ca\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Apprenez-en plus sur les inhibiteurs de JAK topiques contre la dermatite atopique avec la Dre Ashley Sutherland, dermatologue La Soci\u00e9t\u00e9 canadienne de l\u2019ecz\u00e9ma a demand\u00e9 \u00e0 la Dre\u00a0Ashley Sutherland (M.\u00a0Sc., FRCPC), dermatologue, de nous faire part de son expertise au sujet d\u2019Opzelura\u00ae (ruxolitinib), un inhibiteur de JAK topique, dans le traitement de la dermatite atopique [&hellip;]"}